• Elyx 10 years ENG

Innovative financing

Developing sustainable sources of additional funds.    


read more

Market impact

Using secure funding to create incentives for producers.


read more

Healthier people

thank you members





map home-en





UNITAID-funded TB projects

Pushing for scale-up of MDR-TB

UNITAID, together with its partners, is working to increase the number of patients that have access to MDR-TB treatment, accelerate scale-up, and prevent treatment interruption. It is working to reduce drug delivery times from three to six months down to three weeks. UNITAID is also encouraging more producers to enter the market, helping improve quality and reduce prices by up to 25% by 2011.



Rolling out a revolutionary rapid MDR-TB diagnostic

Diagnosing MDR-TB is very difficult, especially in resource-poor settings, where access to laboratories with sophisticated equipment can be limited. A new diagnostic test is now available which cuts the time it takes to diagnose MDR-TB from up to three months down to only two days. UNITAID has committed to funding these tests until 2011, with the aim of facilitating the response to 15% of the global MDR-TB burden, representing a three-fold increase over the current 5% of MDR-TB cases being diagnosed.


2010 update - Strengthening tuberculosis laboratories in Ethiopia what has been accomplished

Expanding access to tuberculosis treatment for children

UNITAID, through it partners, aims to provide more than 750,000 TB treatments to children under the age of 15 by 2011. It is also working to ensure the development and supply of new child-friendly TB formulations for children under four in at least 58 countries by 2011. By helping increase the number of manufacturers, UNITAID has additionally achieved price reductions for paediatric TB medicines of up to 18%. Further, UNITAIDs funding support to WHO has facilitated the prequalification of the first ever paediatric TB medicine.

read more... 


The first-line of defence against emerging resistance: securing first-line TB treatment

UNITAID, through its partner the Global Drug Facility (GDF) of the Stop TB Partnership, is ensuring there is steady availability of first-line drugs in countries by supporting the creation and implementation of a strategic rotating stockpile of first-line TB drugs. The UNITAID-GDF partnership is supporting the diagnosis and treatment of more than 866 000 patients by 2011. UNITAID is also working to stabilize and further reduce prices for first-line drugs through the predictable, long-term funding it provides.


Innovating for Global Health

UNITAID HowWeOperate HP File

High resolution Infographic [JPEG, 4 MB]

  • KPI 2015 WEB v04 1